JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology

  • 0Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia.
Journal of Neuropathology and Experimental Neurology +

|

July 27, 2024

|

July 27, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

OLIG2 immunostaining shows limited utility in differentiating pediatric high-grade gliomas (pHGG) from embryonal tumors (ETs) of the CNS. Integrated diagnostic approaches are crucial for accurate classification of these pediatric CNS neoplasms.

Area Of Science

  • Neuro-oncology
  • Pediatric Pathology
  • Molecular Diagnostics

Background

  • Accurate classification of pediatric central nervous system (CNS) tumors is critical for treatment and prognosis.
  • Distinguishing between pediatric high-grade gliomas (pHGG) and embryonal tumors (ETs) presents diagnostic challenges.
  • OLIG2 immunohistochemistry is a commonly used marker, but its utility in this context requires further evaluation.

Purpose Of The Study

  • To evaluate the diagnostic value of OLIG2 immunohistochemistry in differentiating pediatric high-grade gliomas (pHGG) from embryonal tumors (ETs).
  • To assess the specificity and sensitivity of OLIG2 expression across various pediatric CNS tumor types.
  • To highlight the need for integrated diagnostic strategies in pediatric neuro-oncology.

Main Methods

  • Retrospective analysis of 56 pediatric CNS tumors diagnosed between 1990 and 2021.
  • Reclassification of tumors based on WHO CNS5 criteria, incorporating comprehensive review and molecular testing.
  • Molecular techniques included next-generation sequencing and DNA methylation profiling.

Main Results

  • OLIG2 immunopositivity was negative or minimal in a substantial proportion of pHGG cases (6/11).
  • Diffuse OLIG2 expression was observed in all CNS neuroblastomas with FOXR2 activation (5/5), indicating limited specificity.
  • Variable OLIG2 expression was noted in other ETs, ATRT, and ETMR, with incidental positivity in medulloblastoma and ependymoma.

Conclusions

  • OLIG2 immunostaining alone is insufficient for reliably distinguishing between pHGG and ETs in pediatric CNS neoplasms.
  • The variable and sometimes unexpected expression patterns of OLIG2 complicate its diagnostic utility.
  • An integrated diagnostic approach, combining immunohistochemistry with molecular data, is essential for accurate tumor classification.

Keywords: